NCT00456495View on ClinicalTrials.gov

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

PHASE1CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Conjunctival Neoplasms

Interventions

DRUG

ranibizumab

Subconjunctival injection of drug every 2 to 4 weeks

Trial Locations (1)

10021

The New York Eye Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

The New York Eye Cancer Center

OTHER